Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04920708
Recruitment Status : Not yet recruiting
First Posted : June 10, 2021
Last Update Posted : June 10, 2021
Sponsor:
Collaborators:
Pfizer
Hoffmann-La Roche
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

Brief Summary:
Analysis of circulating tumour DNA (ctDNA) found in a patient's peripheral blood can identify cancer progression and predict a patient's response to therapy. By using ctDNA analysis and imaging techniques, the FAIM trial aims to determine whether the addition of the experimental drug ipatasertib to a standard combination of the hormone treatment fulvestrant and the targeted agent palbociclib increases progression free survival (PFS) for patients with hormone-receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer ER+ Breast Cancer Advanced Breast Cancer Drug: Ipatasertib 300mg Drug: Fulvestrant 500g Drug: Palbociclib 75mg-125mg Drug: CDK4/6 Inhibitor Phase 2

Detailed Description:

Circulating tumour DNA (ctDNA) can be found in the peripheral blood of patients with cancer. ctDNA analysis provides a readily available, serial source of tumour DNA which can be used to monitor disease and predict a patients response to therapy.

Relative changes in ctDNA after 15 days of treatment with palbociclib and fulvestrant has been found to strongly predict progression free survival (PFS) in hormone-receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer patients: patients without ctDNA suppression after 2 weeks of treatment had a significantly shorter PFS compared to those with ctDNA suppression, identifying a group of patients who require additional therapy to prevent early progression.

The FAIM trial is a randomised, open-label study which will aim to determine whether the addition of ipatasertib to standard of care CDK4/6 inhibitors + fulvestrant increases PFS in patients who lack ctDNA suppression after 15 days of treatment. Patients starting standard of care CDK4/6 inhibitors + fulvestrant will have a ctDNA assessment on cycle 1 day 1 (C1D1) and cycle 1 day 15 (C1D15). Those with high ctDNA levels at C1D15 will be randomised on a 1:1 basis to either standard of care (CDK4/6 inhibitors + fulvestrant) or standard of care plus the experimental drug ipatasertib (CDK4/6 inhibitor + fulvestrant + ipatasertib). Patients with ctDNA suppression at C1D15 will continue standard of care (fulvestrant+CDK4/6 inhibitor); the first 100 patients of this group will be followed for PFS and ctDNA collection. Patients without detectable ctDNA on C1D1 will be followed and treated according standard of care; the first 50 patients of this group will be followed for PFS, overall survival (OS), time to next treatment, and time to chemotherapy. Progression free survival will be monitored using RECIST 1.1.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 324 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Patients starting standard of care CDK4/6 inhibitors and fulvestrant will have ctDNA assessment at Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15).

Patients with high ctDNA levels at C1D15 will be randomised in a 1:1 ratio to palbociclib + fulvestrant (comparison arm) or palbociclib + fulvestrant + ipatasertib (interventional arm).

Patients with ctDNA suppressed at C1D15 will continue standard of care, fulvestrant+CDK4/6 inhibitor (observational arm). The first 100 patients of this group will be followed for PFS, OS and ctDNA collection.

Patients with no detectable ctDNA at screening will continue on standard of care. The first 50 of this group will be followed for PFS, OS, time to next treatment, and time to chemotherapy.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised Phase II Study of Induction Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Estimated Study Start Date : August 2021
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Palbociclib + Fulvestrant + Ipatasertib (Interventional arm)
Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to interventional arm receive Palbociclib + Fulvestrant + Ipatasertib. n = 87.
Drug: Ipatasertib 300mg
Ipatasertib 300mg once daily. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
Other Name: RG7440

Drug: Fulvestrant 500g
Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
Other Name: Faslodex

Drug: Palbociclib 75mg-125mg
Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
Other Name: Ibrance

Active Comparator: Palbociclib + Fulvestrant (Comparison arm)
Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to Comparison arm receive Palbociclib + Fulvestrant. n = 87.
Drug: Fulvestrant 500g
Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
Other Name: Faslodex

Drug: Palbociclib 75mg-125mg
Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
Other Name: Ibrance

Active Comparator: Standard of Care (No ctDNA observational arm)
Where no ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 50.
Drug: Fulvestrant 500g
Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
Other Name: Faslodex

Drug: CDK4/6 Inhibitor
CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.
Other Name: Abemaciclib / Ribociclib / Palbociclib

Active Comparator: Standard of Care (Low ctDNA observational arm)
Where low ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 100.
Drug: Fulvestrant 500g
Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
Other Name: Faslodex

Drug: CDK4/6 Inhibitor
CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.
Other Name: Abemaciclib / Ribociclib / Palbociclib




Primary Outcome Measures :
  1. Assess progression free survival (PFS) [ Time Frame: Time from date of randomisation until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 38 months ]
    To compare PFS in patients randomised between palbociclib/fulvestrant/ipatasertib versus standard of care palbociclib-fulvestrant alone, in advanced ER+/HER2- breast cancer patients with trackable mutations and high ctDNA after 2 weeks of CDK4/6 inhibitor/fulvestrant.


Secondary Outcome Measures :
  1. Use NCI CTCAE V5.0 to assess safety and tolerability of palbociclib/fulvestrant/ipatasertib compared to palbociclib/fulvestrant alone [ Time Frame: 36 months (treatment duration + follow-up duration) ]
    • To assess the overall safety and tolerability of palbociclib/fulvestrant/ipatasertib compared to standard of care palbociclib/fulvestrant alone. Safety will be evaluated continuously using NCI CTCAE V5.0.

  2. Assess overall survival [ Time Frame: 36 months (treatment duration + follow-up duration) ]
    • To assess overall survival in patients receiving palbociclib/fulvestrant/ipatasertib compared to standard of care palbociclib/fulvestrant alone

  3. Assess objective response rate [ Time Frame: 36 months (treatment duration + follow-up duration) ]
    • To assess the objective response rate in patients receiving palbociclib/fulvestrant/ipatasertib compared to standard of care palbociclib/fulvestrant alone

  4. Report progression free survival (PFS) in patients with low ctDNA and high ctDNA [ Time Frame: Time from date of randomisation until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 38 months ]
    • To report PFS in patients with high ctDNA randomised to standard of care palbociclib/fulvestrant alone with those with suppressed ctDNA on standard of care CDK4/6 inhibitor/fulvestrant alone (observational arm)

  5. Compare progression free survival (PFS) in the subgroup of advanced ER+/HER2- breast cancer patients [ Time Frame: Time from date of randomisation until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 38 months ]
    o compare PFS in patients randomised between palbociclib/fulvestrant/ipatasertib and palbociclib/fulvestrant alone, in the subgroup of advanced ER+/HER2- breast cancer patients with PIK3CA/PTEN/AKT1 mutations or PTEN loss and high ctDNA on palbociclib/fulvestrant


Other Outcome Measures:
  1. Evaluate changes in ctDNA in patients with high ctDNA C1D15 [ Time Frame: 36 months (treatment duration + follow-up duration) ]
    • To evaluate changes in ctDNA in patients randomised to palbociclib/fulvestrant/ipatasertib or standard of care palbociclib/fulvestrant alone.

  2. Compare progression free survival (PFS) in patients with high ctDNA at C1D15 and genetic alterations identified in ctDNA sequencing. [ Time Frame: 36 months (treatment duration + follow-up duration) ]
    • To compare PFS in patients randomised between SOC palbociclib/fulvestrant + /ipatasertib and SOC palbociclib/fulvestrant alone, in subgroups of advanced ER+/HER2- breast cancer patients with genetic alterations identified in ctDNA sequencing data.

  3. Report progression free survival (PFS) in patients with undetectable ctDNA and those with detected ctDNA at C1D1 with and without suppression at C1D15. [ Time Frame: 36 months (treatment duration + follow-up duration) ]
    • To compare report PFS in patients with undetectable ctDNA at Cycle 1 Day 1 and those with detectable ctDNA with and without ctDNA suppression at Day 15.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histological diagnosis of metastatic or inoperable locally advanced ER positive/HER2 negative breast cancer. Assessment of ER and HER2 status as per local assessment. Histologically proven primary ER+ (Allred score 3/8 or greater, or stain in >1% of cancer cells) and HER2- (immunohistochemistry 0/1+ or negative by in situ hybridization) breast cancer as determined by local laboratory.
  2. Be willing to consent for an archival tumour tissue sample (of advanced disease) to be requested for transfer to the Royal Marsden for future review during study screening. Patients without a metastatic biopsy may be eligible if archival tumour from the breast primary tumour is available, but only after discussion with the Chief Investigator.
  3. Previously treated with no more than one prior line of chemotherapy for advanced disease.
  4. Patients eligible according to standard of care for fulvestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib).
  5. Patients must have received at least one prior line of hormone therapy for advanced disease and progressed on or within 1 month from stopping prior endocrine therapy for advanced disease, or relapsed on or within 12 months of completing adjuvant endocrine therapy.
  6. Measurable disease (RECIST 1.1) or assessable bone disease (lytic or mixed lytic sclerotic).
  7. Eastern Cooperative Oncology Group (ECOG) performance status 0,1 or 2.
  8. Estimated life expectancy of at least 3 months.
  9. Adequate bone marrow, renal, and liver function within 14 days before the first study treatment on Day 1 of Cycle 1, defined by the following:

    1. Neutrophils (ANC ≥ 1500/μL), Haemoglobin ≥9 g/dL, Platelet count ≥100,000/μL
    2. Serum albumin ≥3 g/dL
    3. Total bilirubin ≤1.5 x the upper limit of normal (ULN), with the following exception: patients with known Gilbert syndrome who have serum bilirubin ≤3 x ULN may be enrolled
    4. AST and ALT ≤2.5 x ULN, with the following exception: patients with documented liver or bone metastases may have AST and ALT ≤5 x ULN.
    5. ALP ≤2 x ULN, with the following exceptions: patients with known liver involvement may have ALP ≤5 x ULN, patients with known bone involvement may have ALP ≤7 x ULN
    6. Serum creatinine ≤1.5 x ULN or creatinine clearance ≥50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation.
    7. INR <1.5 x ULN and aPTT <1.5 x ULN. Patients requiring formal anticoagulation should receive either low-molecular weight heparin or a direct oral anticoagulant.
  10. Fasting glucose ≤150mg/dL and HbA1c ≤7.5%.
  11. Negative serum pregnancy test at screening (females of childbearing potential).
  12. Patients able to have children must agree to use two highly effective methods of contraception throughout the study and for 2 years after last dose of fulvestrant and at least two years after last dose. Patients must additionally agree to refrain from donating eggs during this period.
  13. Signed and dated informed consent.
  14. Patients willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other procedures.
  15. Pre/peri-menopausal patients must be treated with GnRH agonist beginning at least 7 days prior to Day 1 of Cycle 1 and continuing every 28 days for the duration of study treatment.

Exclusion Criteria:

  1. Previous fulvestrant and CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) in any setting.
  2. Prior use of AKT inhibitor (any setting).
  3. History of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills.
  4. Systemic chemotherapy within 14 days prior to study entry.
  5. Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry.
  6. Patients with known leptomeningeal disease, symptomatic brain metastases requiring steroids, untreated brain metastases or spinal cord compression.
  7. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including any of the following:

    1. History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 12 months prior to study entry.
    2. Known (documented) cardiomyopathy, i.e known left ventricular ejection fraction (LVEF) < 50% (ECHO or MUGA not needed specifically for this trial).
    3. History of symptomatic cardiac failure (NYHA class II-IV or LVEF <50%), uncontrolled hypertension, cardiac dysrhythmia including atrial fibrillation requiring medication, significant/symptomatic bradycardia, Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following:, cerebrovascular accident, or transient ischemic attack within 12 months; known risk factors for prolonged QT interval or Torsade's de Pointes; Uncorrected hypomagnesaemia or hypokalaemia of Grade 3 or higher; Systolic Blood Pressure (SBP) >160 mmHg or <90 mmHg; Bradycardia (heart rate <50 at rest), by ECG (based on a mean of 3 ECGs) or pulse; On screening, QTcF >470 screening ECG (based on a mean of 3 ECGs).
  8. Pneumonitis, interstitial lung disease or pulmonary fibrosis.
  9. Type I or II diabetes requiring insulin.
  10. Use of drugs that are known potent cytochrome P450 3A inducers or inhibitors within 2 weeks or 5 elimination half-lives (whichever is longer) before the first dose of study drug.
  11. Known HIV or AIDS-related illness.
  12. Active infection requiring systemic therapy.
  13. Known positive HBV or HCV test indicating acute or chronic infection

    1. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible.
    2. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  14. Clinically significant liver disease consistent with Child Pugh class B or C.
  15. Administration of a live vaccine within 4 weeks prior to study entry.
  16. Diagnosis of other malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix.
  17. Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation.
  18. Persisting toxicity related to prior therapy >Grade 1 (except for stable peripheral neuropathy grade 2 or alopecia grade 2).
  19. Other severe acute or chronic medical condition, including colitis, inflammatory bowel disease, psychiatric condition, recent or active suicidal ideation or behaviour, or end stage renal disease on haemodialysis, or laboratory abnormality that may increase the risk associated with study participation or investigational products administration or may interfere with the interpretation of results and, in the judgment of the Investigator, would make the patient inappropriate study entry.
  20. Radiation therapy (other than palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of study treatment.
  21. Palliative radiation to bony metastases within 2 weeks prior to initiation of study treatment.
  22. Allergy or hypersensitivity to components of the ipatasertib, palbociclib, or fulvestrant.
  23. Patients able to have children who are unwilling or unable to use 2 highly effective method(s)¹ of contraception for the duration of the study and for at least 60 days after the last dose of investigational product. Patient pregnant or breastfeeding.
  24. Need for chronic corticosteroid therapy of >10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04920708


Contacts
Layout table for location contacts
Contact: Project Manager 020 7808 2887 faim@rmh.nhs.uk

Locations
Show Show 20 study locations
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Pfizer
Hoffmann-La Roche
Investigators
Layout table for investigator information
Principal Investigator: Alicia Okines Royal Marsden NHS Foundation Trust
Publications:
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.

Layout table for additonal information
Responsible Party: Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT04920708    
Other Study ID Numbers: CCR5214
First Posted: June 10, 2021    Key Record Dates
Last Update Posted: June 10, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The confidentiality of patients participating in this trial will be protected and each participant will be assigned a unique trial number at the point of registration which will be used to identify eCRFs and anything else sent to the sponsor or other third parties. No patient identifiable data will be shared outside of the participating site.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Royal Marsden NHS Foundation Trust:
Fulvestrant
Palbociclib
Ipatasertib
ctDNA
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Fulvestrant
Palbociclib
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action